Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. (www.atarabio.com) is engaged in developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers and autoimmune disease. The Company’s pipeline products include Tab-cel and ATA188, as well as ATA2271, ATA3271 and ATA3219 under CAR T Programs. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. The Company’s ATA188 is a T-cell immunotherapy targeting EBV antigens for the treatment of multiple sclerosis. Its ATA2271 is an autologous chimeric antigen receptors (CAR) T immunotherapy targeting solid tumors expressing the tumor antigen mesothelin.

• Atara Biotherapeutics, Inc.